The business has announced its acquisition of Softbox, a provider of passive temperature-controlled packaging solutions for the pharmaceutical, life science and cold chain logistics industries, significantly enhancing CSafe's passive product portfolio.
Together, they will provide the most comprehensive suite of thermal shipping solutions and become a one-stop-shop for all pharmaceutical cold chain shipping needs, enabling delivery of critical temperature-sensitive products, including next generation biologics, cell and gene therapy, and mRNA therapies such as the COVID-19 vaccine.
The combined company, which will operate globally under the CSafe brand, will be the only cold chain platform with an end-to-end active air cargo and passive temperature-controlled packaging business spanning the complete spectrum of cold chain shipping solutions for the pharmaceutical and life sciences industries. As part of the acquisition, Softbox CEO Kevin Valentine will assume the role of president of CSafe's Passive Temperature Controlled Packaging Division.
Patrick Schafer, CSafe CEO, said "Through this combination, we will be the partner of choice for cold chain delivery of high value, temperature sensitive pharmaceutical therapies. Both CSafe and Softbox have proven to be reliable partners for customers seeking a secure way to deliver their life-enhancing products around the world."
Kevin Valentine, CEO of Softbox, said "Our businesses are each rooted in a commitment to excellent customer service and high product quality, which made this combination a natural fit. Together we will proudly continue to partner with our global pharmaceutical customers to devise and deliver the best solutions for their evolving cold chain shipping needs, supporting the delivery of temperature sensitive lifesaving medicines and vaccines.”
Liberty advised the Softbox management team, led by CEO Kevin Valentine, on all aspects of their new management incentive arrangements.